GE Aerospace is a publicly traded company in the Manufacturing sector. As an industrial manufacturer, this company benefits from or is challenged by Buy America provisions, trade tariffs, supply chain legislation, and infrastructure spending mandates. HillSignal is tracking 5 active Congressional signals mentioning GE Aerospace, including 5 bills. The current legislative sentiment is predominantly bullish, suggesting potential tailwinds from government policy.
S.257, the Promoting Resilient Supply Chains Act of 2025, passed the Senate in June 2025 and moves to the House. The bill establishes a regulatory coordination framework for monitoring and strengthening critical U.S. supply chains but authorizes zero funding. The structural beneficiary set includes domestic industrial equipment manufacturers ($CAT, $DE) and defense primes ($GE, $RTX, $NOC). $CAT has rallied +24.41% in the last 30 days to $881.38, reflecting broad industrial momentum that this bill's policy tailwind reinforces for the longer term.
HR5862 proposes restoring energy tax incentives rolled back under Public Law 119-21, targeting renewable project tax credits and domestic oil/gas/coal deductions. Combined with April 2026 DPA memoranda accelerating grid, natural gas, and coal infrastructure, the legislative package amplifies tailwinds across the energy sector. At early-stage referral, no funding is appropriated, but tax provisions create direct structural benefits for renewable developers, midstream operators, E&P companies, and coal miners.
The SAF Act (HR6518) would reinstate and extend premium tax credits for sustainable aviation fuel through 2033, improving producer economics by $0.75/gallon over standard clean fuel credits. The bill is in early stage (referred to Ways and Means). Pure-play beneficiaries include refiners with conversion capacity like HF Sinclair (DINO) and engine suppliers like GE Aerospace (GE). No market data provided.
HR1990, the American Innovation and R&D Competitiveness Act, would restore immediate expensing for R&D costs, reversing the 2022 tax code change that required 5/15-year amortization. This is an early-stage bill referred to Ways and Means with 81 cosponsors, but if enacted, it would provide a direct 21% tax-rate cash flow benefit annually to every R&D-intensive US company. The largest absolute beneficiaries are mega-cap tech and pharma firms with $10B+ annual R&D budgets.
The Export-Import Bank Reauthorization Act (S. 3772) is early-stage legislation extending Ex-Im's charter to 2036 and loan authority to 2037. This bill removes sunset risk for U.S. exporters of capital goods — primarily commercial aircraft (Boeing), heavy machinery (Caterpillar), and industrial equipment (GE Aerospace / GE Vernova). The bill authorizes no direct spending; it extends existing financing tools that support ~$10B+ in annual export sales. At current stage (referred to committee), market impact is procedural but structural.